Gibson Dunn Advises Natera on Acquisition of Foresight Diagnostics

Firm News  |  December 5, 2025

---

Gibson Dunn advised Natera, Inc., a global leader in cell-free DNA and precision medicine, on its acquisition of Foresight Diagnostics, a leader in ultrasensitive molecular residual disease detection.

Our corporate team included partners Branden Berns, Gina Hancock, and Jin Hee Kim.